Compare

Oxytocin vs PT-141

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Oxytocin

1645 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 49% · Mixed 42% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Focus
-20
Sleep quality
-60
Lean mass
-87
Joint comfort
-91
Recovery
-69

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Nausea
-104
Water retention
-160
Appetite loss
-122
Injection site reaction
-95
Anxiety
-69

Self-reported dose per injection

Median bucket: 200–400 mcg · Most common: 400–600 mcg

Reports span 50–1000 mcg

50–100
6
100–200
10
200–400
16
400–600
17
600–1000
10

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing49stacking17side effects15oxytocin28

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 41% more positive, and 19% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 21 days · Based on 362 repeat reporters

PT-141

1941 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 45% · Mixed 38% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
-68
Appetite control
-111
Energy
-94
Mood
-47
Focus
-86

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
-152
GI discomfort
-31
Dizziness
-129
Fatigue
-51
Nausea
-86

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.2–0.4 mg

Reports span 0.05–2 mg

0.05–0.1 mg
7
0.1–0.2 mg
15
0.2–0.4 mg
23
0.4–0.6 mg
12
0.6–1 mg
7
1–2 mg
1

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing25stacking18side effects11pt-14124

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 31% more positive, and 15% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 29 days · Based on 427 repeat reporters

Sources (9)

Published sources linked on the Oxytocin and PT-141 wiki pages.

  1. PubMed

    Intranasal oxytocin in humans: a review of neurobiological and behavioral effects

    Striepens N, Kendrick KM, Maier W, et al. Prog Neuropsychopharmacol Biol Psychiatry. 2013

    Source
    Wiki study page →
  2. FDA Drug Label

    PITOCIN (oxytocin) injection — Prescribing Information

    Par Pharmaceutical. FDA Drug Label. 2014

    Source
    Wiki study page →
  3. PubMed

    Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress

    Heinrichs M, Baumgartner T, Kirschbaum C, et al. Biological psychiatry. 2003

    Source
    Wiki study page →
  4. PubMed

    Intranasal oxytocin as a treatment for anxiety and autism: From subclinical to clinical applications

    Yin H, Jiang M, Han T, et al. Peptides. 2024

    Source
    Wiki study page →
  5. FDA Drug Label

    VYLEESI (bremelanotide injection) for subcutaneous use - Prescribing Information

    AMAG Pharmaceuticals. FDA Drug Label. 2019

    Source
    Wiki study page →
  6. PubMed

    Bremelanotide: New Drug for Treating Hypoactive Sexual Desire Disorder

    Kingsberg SA, Clayton AH, Portman D, et al. Obstet Gynecol. 2019

    Source
    Wiki study page →
  7. ClinicalTrials.gov

    Bremelanotide (PT-141) studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  8. PubMed

    Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment

    Pettigrew JA, Novick AM. Journal of midwifery & women's health. 2021

    Source
    Wiki study page →
  9. PubMed

    Pharmacologic therapeutic options for sexual dysfunction

    Burton CS, Mishra K. Current opinion in obstetrics & gynecology. 2022

    Source
    Wiki study page →